Marketing copy is not a layer on top of a regulated product. In the cell and tissue field, the words on a stem cell clinic’s website help decide how federal agencies classify what it sells. This guide covers the agencies, the standards they apply, and the enforcement record.
TLDR FDA and FTC regulate health advertising on separate tracks under separate laws. FDA rules name advertising itself as evidence of a product’s intended use, and the FTC requires competent and reliable scientific evidence behind every health claim. Published warning letters and court orders show both agencies quoting company marketing back at the company. Adipose tissue banking is preservation only, is not FDA approved for any disease, and does not guarantee eligibility, access, or clinical benefit.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease, including the orthopedic and neurological conditions named in the enforcement records described below. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. No adipose-derived stem cell product currently has FDA approval for any disease. All content is for educational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions.
Most people read a clinic’s website as sales copy. Regulators read it as evidence. One of the four criteria in 21 CFR 1271.10 asks whether a product is “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer’s objective intent.” A landing page is therefore a regulatory input.
Two agencies enforce here, separately. FDA regulates the product, including labeling and what marketing shows about intended use. The FTC regulates advertising, and its enforcement here has charged false or unsubstantiated efficacy representations under 15 U.S.C. 45(a) and 52. No joint FDA and FTC statement or sweep exists.
Why FDA Rules Treat Advertising as Evidence
Because the regulation says so. A cell or tissue product stays under the lighter section 361 pathway only if it meets all four criteria at 1271.10(a). The second is judged by labeling and advertising.
Fail a criterion and, under section 1271.20, the product “will be regulated as a drug, device, and/or biological product.” That means an investigational new drug application to study it and a biologics license application to market it.
Homologous use has a fixed regulatory definition: use of a product that “performs the same basic function or functions in the recipient as in the donor.” The July 2020 guidance says using adipose tissue for a “degenerative, inflammatory, or demyelinating disorder would generally be considered a non-homologous use.” The advertised purpose decides which fits.
What the FTC Considers a Deceptive Health Claim
A claim is deceptive when the advertiser cannot support it with competent and reliable scientific evidence. The FTC’s Health Products Compliance Guidance, published December 20, 2022, draws on more than 200 FTC cases settled or adjudicated since 1998.
It defines that evidence as “tests, analyses, research, or studies” evaluated objectively by experts and “generally accepted in the profession to yield accurate and reliable results.” Randomized controlled human trials are “the most reliable form of evidence.”
Disclosures carry their own standard. They must be “easily noticeable” and understandable to ordinary consumers, unavoidable in digital media, and never parked behind a hyperlink. Qualifiers such as “may” or “preliminary” are inadequate to communicate scientific limitations.
How the Endorsement Guides Handle Testimonials
They deny testimonials the status of proof. The Endorsement Guides at 16 CFR Part 255, published July 26, 2023 at 88 FR 48102, close section 255.2 with one line: “Consumer endorsements themselves are not competent and reliable scientific evidence.”
The compliance guidance agrees. It is “not enough that a testimonial represents the honest opinion or experience of an endorser.” Advertisers “must have appropriate scientific evidence to back up the underlying implied claim that the product is effective.” A “Results not typical” line does not correct deception, and the material connection rule requires disclosing a relationship the audience would not expect.
What FDA Warning Letters Actually Cite
They cite the product, the process, and the promotion together. The products at issue include umbilical cord, Wharton’s jelly, amniotic fluid, and exosomes.
| Firm and letter date | What FDA cited |
|---|---|
| Dynamic Stem Cell Therapy, February 11, 2026 | Unapproved new drug and unlicensed biologic, failed minimal manipulation and homologous use, misbranding. FDA quoted marketing for knee pain, spinal cord injury, and arthritis |
| New Life Medical Services, September 24, 2025 | FD&C 505(a) and 301(d), PHS 351(a)(1) and 361, plus 21 CFR 1271.10(a) and 1271.20. FDA listed marketed applications including hair restoration |
| Supreme Rejuvenation, May 5, 2025 | Unapproved new drugs and unlicensed biologics, on claims naming arthritis, COVID-19 long-haulers, dementia, diabetic patients, and fibromyalgia |
| Chara Biologics, January 17, 2025 | Unapproved new drug and unlicensed biologic on marketing naming Parkinson’s, Alzheimers, Multiple Sclerosis and ALS, plus no quality unit |
| BioStem Life Sciences, January 17, 2025 | Manufacturing quality: environmental monitoring, unvalidated cleanroom cleaning for ISO 5 and ISO 7 areas, process validation, expiration dates set without stability data |
The pattern matters more than any firm. In four of the five, the trigger is advertising and website copy, not biology alone, as our overview of FDA warning letters shows.
The Two FTC Enforcement Actions Against Stem Cell Marketers
There are two, both in federal court, and no third exists. The first, FTC Matter No. 172-3062 against Regenerative Medical Group, Telehealth Medical Group, and Bryn Jarald Henderson, D.O., ended in a stipulated order in October 2018.
The FTC challenged claims that an “amniotic stem cell therapy” could treat Parkinson’s disease, autism, macular degeneration, cerebral palsy, multiple sclerosis and osteoarthritis. The 2018 order carried a $3.31 million judgment, partially suspended upon payment of $525,000.
The second is FTC and State of Georgia v. Steven D. Peyroux, Brent J. Detelich and others, Matter No. 182-3125. The FTC and the Georgia Attorney General filed it jointly on August 17, 2021 in the Northern District of Georgia. The court granted summary judgment for the plaintiffs on all five counts in an order filed March 11, 2024.
Relief orders filed December 26, 2024 total $5,155,146: restitution of $3,310,146 and civil penalties of $1,845,000. Those civil penalties came under the Georgia Fair Business Practices Act, not the FTC Act, and a federal court awarded them in a joint federal and state action. The orders permanently prohibit the defendants from “advertising, marketing, promoting, offering for sale, or selling any regenerative medicine treatments.” Our FTC enforcement pattern guide compares both actions.
What the Federal Courts Decided About the Products
Two federal cases reached the products themselves. A federal court decision of June 3, 2019 held that the US Stem Cell Clinic defendants “adulterated and misbranded their cellular products made from patients’ adipose tissue.” The Eleventh Circuit opinion affirmed on June 2, 2021, holding that stromal vascular fraction is a “drug” under federal law. In the other case, against California Stem Cell Treatment Center, Inc. and Cell Surgical Network, the government lost at trial and won on appeal in the Ninth Circuit.
How to Read a Clinic’s Marketing Against These Rules
Start with what the claim would require. Under the FTC standard, a health benefit claim needs competent and reliable scientific evidence, and testimonials do not supply it. Under the FDA framework, a claim that a tissue product addresses a degenerative, inflammatory, or demyelinating disorder describes a non-homologous use.
Registration is a second common misreading. Registering an establishment and listing a product with FDA is self-submitted, not approval, endorsement, or clearance. FDA states on its patient information page that the fact “a firm has registered with FDA and listed its product does not mean the product is legally marketed.”
The same page tells patients that being “charged for these products or offered these products outside of a clinical trial” means they are “likely being deceived and offered a product illegally.” FDA’s consumer alert adds that no regenerative medicine products are approved for orthopedic conditions, neurological disorders, cardiovascular or pulmonary disease, autism, blindness, or chronic pain.
As of March 2021, a published census counted 1,480 U.S. businesses operating 2,754 clinics selling purported stem cell treatments. Several states add informed-consent and disclosure rules, compared in our advertising disclosure laws guide.
What This Means for Adipose Tissue Banking
Banking is preservation, not treatment. Save My Fat is a connector that links patients and providers with a U.S. tissue bank. It does not collect, process, store, or treat tissue, and it is not a clinic or a medical practice. Adipose tissue and anything derived from it, including stromal vascular fraction and exosomes, is investigational and not FDA approved for any disease. Any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Frequently Asked Questions
Do these advertising rules apply to a clinic’s website?
Yes. The homologous use criterion at 21 CFR 1271.10(a)(2) names labeling, advertising, and other indications of objective intent, and FDA quoted firms’ own marketing in four of the five letters above.
Can a clinic rely on patient testimonials as proof?
No. The Endorsement Guides state that “consumer endorsements themselves are not competent and reliable scientific evidence,” and a “Results not typical” disclaimer does not correct an unsubstantiated claim.
Is there a joint FDA and FTC rule on stem cell advertising?
No joint statement or sweep exists. The agencies work separate tracks under separate authorities. FDA’s own 2019 action, without the FTC, put R3 Stem Cell and its chief executive on notice with more than 50 affiliate clinics.
Key Takeaways
Advertising is a regulatory input, not a separate marketing layer. The criterion at 21 CFR 1271.10(a)(2) makes labeling and advertising the test of intended use, and FDA quoted company marketing in four of the five letters above. The FTC requires competent and reliable scientific evidence for every health claim, and testimonials do not qualify. The two federal FTC actions produced a partially suspended $3.31 million judgment and a $5,155,146 relief total whose civil penalties came under Georgia law. Adipose tissue banking is preservation only and guarantees no eligibility, access, or clinical benefit.
Save My Fat connects patients and providers with a U.S.-based tissue bank. It is not a tissue bank, a laboratory, a medical practice, or a treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, California, Georgia, and Tennessee governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Readers weighing adipose tissue banking for potential future use can review current pricing or start a conversation through the contact page.
Save My Fat works with a U.S.-based tissue bank for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Please consult your own licensed healthcare provider before making any decisions about adipose tissue banking or research participation.
About the author: Oscar Tellez is the founder and CEO of Save My Fat. He holds a Bachelor of Science in Exercise Science and Health Promotion from Florida Atlantic University. He has spent a decade in the regenerative medicine industry across product distribution, laboratory and vendor relationships, and provider training. He is not a licensed clinician, and this article is educational, not medical advice.
Related guide: compliant marketing standards.
